Sangamo Therapeutics (NASDAQ:SGMO) Upgraded at StockNews.com

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other equities research analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday. Barclays raised their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday.

Sangamo Therapeutics Trading Down 4.7 %

Shares of NASDAQ SGMO opened at $2.05 on Thursday. The stock has a market cap of $427.67 million, a P/E ratio of -2.73 and a beta of 1.10. The business’s fifty day simple moving average is $1.33 and its 200-day simple moving average is $0.86. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in shares of Sangamo Therapeutics by 58.8% during the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after acquiring an additional 1,528,600 shares during the period. Acadian Asset Management LLC boosted its holdings in Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Marshall Wace LLP increased its position in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its position in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.